Orphan nuclear receptor COUP-TFII drives the myofibroblast metabolic shift leading to fibrosis

Li Li, Pierre Galichon, Xiaoyan Xiao, Ana C Figueroa‐Ramirez, Diana Tamayo, Jake June-Koo Lee, Marian Kalocsay, David G Gonzalez-Sanchez, Maria S Chancay, Kyle W. McCracken, Darío R. Lemos, Nathan Lee, Takaharu Ichimura, Yutaro Mori, M. Todd Valerius, Xiaoming Sun, Elazer R. Edelman, Joseph V. BonventrebioRxiv 2020 · DOI

TL;DR

This study identifies COUP-TFII as a key regulator of metabolic reprogramming in myofibroblasts, driving fibrosis by shifting cells from oxidative metabolism to aerobic glycolysis. Targeting COUP-TFII shows promise as a novel therapeutic strategy for treating fibrotic diseases.

What Problem Does This Paper Address?

Fibrosis, the excessive deposition of extracellular matrix, is a hallmark of many chronic diseases, including kidney disease, liver cirrhosis, and lung fibrosis, ultimately leading to organ failure. While metabolic disturbances, particularly augmented glycolysis, have been implicated in fibrosis, the precise molecular mechanisms driving these changes in myofibroblasts (the primary cells responsible for fibrosis) remain poorly understood. This knowledge gap hinders the development of effective anti-fibrotic therapies. This paper aims to elucidate the role of COUP-TFII, a known regulator of glucose and lipid metabolism, in this process.

Methods

The researchers employed a multi-pronged approach:

  • Human Tissue and Organoid Analysis: They examined human kidney and lung tissues from patients with fibrotic conditions, as well as human kidney organoids, to assess COUP-TFII expression levels and localization.
  • Animal Models: They utilized mouse models of kidney injury (unilateral ureteral obstruction and ischemia-reperfusion injury) to study the temporal and spatial expression of COUP-TFII during fibrosis development.
  • Genetic Manipulation: They used genetically modified mice (COUP-TFII knockout models) to investigate the functional consequences of COUP-TFII ablation on fibrosis.
  • Cell Culture and Manipulation: They generated cell lines with COUP-TFII knockout or overexpression using CRISPR-Cas9 and lentiviral constructs in a pericyte-like cell line (C3H/10T1/2).
  • Proteomics and Gene Expression Analysis: Non-biased proteomic studies (GSEA) were performed on manipulated cells to identify affected metabolic pathways. qRT-PCR was used to quantify gene expression changes.
  • Metabolic Assays: Seahorse XF analysis was employed to measure real-time cellular metabolism (glycolysis and mitochondrial respiration).
  • ChIP-qPCR: This technique was used to investigate the direct binding of COUP-TFII to the promoter of PGC1α, a key regulator of mitochondrial function.

Datasets

  • Human Kidney Microarray Data: Publicly available datasets (GSE66494) of kidney biopsy tissues from patients with chronic kidney disease (CKD) were analyzed for COUP-TFII mRNA levels.
  • Human Kidney Samples: Samples from patients with thrombotic microangiopathy (TMA) and diabetic nephropathy (DN) were used for immunostaining.
  • Human Lung Samples: Samples from patients with idiopathic pulmonary fibrosis (IPF) were used for immunostaining.
  • Human Kidney Organoids: These were generated from H9 human embryonic stem cells and used to model fibrotic kidney disease.
  • Single-cell RNA sequencing database: An available database (http://humphreyslab.com/SingleCell/) was analyzed to assess COUP-TFII RNA enrichment in pericyte/fibroblast cells in both human and mouse injured kidneys.

Key Insights and Ideas

  • COUP-TFII is a "Fibrosis Switch": The study strongly suggests that COUP-TFII acts as a critical switch, reprogramming myofibroblast metabolism from energy-efficient oxidative respiration to less efficient but more proliferative aerobic glycolysis. This shift fuels the production of fibrotic mediators.
  • Metabolic Reprogramming is Central to Fibrosis: This work highlights that metabolic changes are not just a consequence of fibrosis but are actively driven by key transcription factors like COUP-TFII, playing a causal role in the fibrotic process.
  • Targeting Metabolism for Anti-Fibrotic Therapy: By identifying a specific metabolic regulator, the study opens up new avenues for therapeutic intervention, moving beyond targeting general fibrotic pathways to targeting the underlying metabolic drivers.
  • Shared Pathway Across Fibrotic Diseases: The findings in kidney fibrosis suggest that COUP-TFII's role in metabolic reprogramming might be a common pathway in various fibrotic conditions, making it a potentially broad therapeutic target.

Key Results

  • Increased COUP-TFII in Fibrosis: COUP-TFII expression was significantly elevated in myofibroblasts in human fibrotic kidneys and lungs, as well as in fibrotic human kidney organoids and injured mouse kidneys.
  • Ablation Attenuates Fibrosis: Genetic deletion of COUP-TFII in adult mice significantly reduced injury-induced kidney fibrosis, with decreased αSMA and collagen1 expression.
  • Metabolic Shift: Overexpression of COUP-TFII in fibroblasts led to enhanced glycolysis and suppressed fatty acid oxidation. Conversely, knockout of COUP-TFII reduced glycolysis.
  • PGC1α Regulation: COUP-TFII was found to bind to the promoter of PGC1α, a key regulator of mitochondrial biogenesis, and its overexpression reduced PGC1α levels.
  • Glycolysis Inhibition Reduces Fibrosis Markers: Inhibiting glycolysis with 2-deoxyglucose (2-DG) in COUP-TFII overexpressing cells reduced αSMA and collagen1 expression.

Limitations and Future Work

  • In Vitro vs. In Vivo: While the study provides strong evidence from both in vitro and in vivo models, further research is needed to fully elucidate the complex interplay of COUP-TFII in the in vivo microenvironment.
  • Specificity of Targeting: While COUP-TFII expression is primarily in myofibroblasts, ensuring selective targeting without affecting other cell types will be crucial for therapeutic development.
  • Therapeutic Development: The authors suggest that targeting COUP-TFII is a promising therapeutic approach. Future work would involve developing and testing specific inhibitors or modulators of COUP-TFII activity in preclinical and clinical settings.
  • Broader Organ Fibrosis: The study focused on kidney fibrosis, but the authors hypothesize that COUP-TFII's role in metabolic reprogramming may extend to other fibrotic organs, warranting further investigation in those contexts.

Summary updated

Abstract

ABSTRACT Recent studies demonstrated that metabolic disturbance, such as augmented glycolysis, contributes to fibrosis. The molecular regulation of this metabolic perturbation in fibrosis, however, has been elusive. COUP-TFII (also known as NR2F2) is an important regulator of glucose and lipid metabolism. Its contribution to organ fibrosis is undefined. Here, we found increased COUP-TFII expression in myofibroblasts in kidneys of patients with chronic kidney disease, fibrotic lungs of patients with idiopathic pulmonary fibrosis, fibrotic human kidney organoids, and fibrotic mouse kidneys after injury. Genetic ablation of COUP-TFII in mice resulted in attenuation of injury-induced kidney fibrosis. A non-biased proteomic study revealed the suppression of fatty acid oxidation and the enhancement of glycolysis pathways in COUP-TFII overexpressing fibroblasts. Overexpression of COUP-TFII in fibroblasts was sufficient to enhance glycolysis and increase alpha smooth muscle actin (αSMA) and collagen1 levels. Knockout of COUP-TFII decreased glycolysis and collagen1 levels in fibroblasts. Chip-qPCR assays revealed the binding of COUP-TFII on the promoter of PGC1α, a critical regulator of mitochondrial genesis and oxidative metabolism. Overexpression of COUP-TFII reduced the cellular level of PGC1α. In conclusion, COUP-TFII mediates fibrosis by serving as a key regulator of the shift in cellular metabolism of interstitial pericytes/fibroblasts from oxidative respiration to aerobic glycolysis. The fibrogenic response may share a common pathway in different organ injury and failure. Targeting COUP-TFII serves as a novel treatment approach for mitigating fibrosis in chronic kidney disease and potential other organ fibrosis.
BibTeX
@misc{li2020orphan,
  author = {Li Li and Pierre Galichon and Xiaoyan Xiao and Ana C Figueroa‐Ramirez and Diana Tamayo and Jake June-Koo Lee and Marian Kalocsay and David G Gonzalez-Sanchez and Maria S Chancay and Kyle W. McCracken and Darío R. Lemos and Nathan Lee and Takaharu Ichimura and Yutaro Mori and M. Todd Valerius and Xiaoming Sun and Elazer R. Edelman and Joseph V. Bonventre},
  title = {{Orphan nuclear receptor COUP-TFII drives the myofibroblast metabolic shift leading to fibrosis}},
  year = {2020},
  doi = {10.1101/2020.06.05.135889},
  howpublished = {bioRxiv},
}
Figure